Telotristat Makes Significant Difference on Symptoms and Serotonin Levels in a Population with Widespread GI-NET and Severe Carcinoid Syndrome Abstract #3075

Introduction: In spite of new treatments like PRRT or everolimus there is a clinical need for systemic therapies that complement SSAs (somatostatin analogs) and antidiarrheal agents in the treatment of carcinoid syndrome, a late stage problem in s-i-NET. Telotristat is a promising addition to our therapeutic arsenal.
Aim(s): To monitor effects and side effects of the new tryptophan hydroxylase inhibitor telotristat in a population with late stage metastasized GI-NET disease with ongoing highdose SSA and often earlier Lutetium or interferon treatment.
Materials and methods: 16 patients in Karolinska Endocrine Tumor department were treated with telotristat in increasing doses from 250 mg to 750 mg daily. They had metastasized disease in liver, lymphnodes, or skeleton, G1(4) or G2(12) and high dU-5-HIAA or S-5-HIAA (4-18 times ULN). Most hade earlier received gut surgery, SSA (ongoing every second-third week injection) and Lutetium (8/12) or Sirtex(1) but progressed symptomatically, biochemically and radiologically.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: MD PhD Kristina Linder Ekberg
Authors: Linder Ekberg K

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2840 A Real-World Study of Patients with Carcinoid Syndrome at King’s College Hospital on Long-Term Telotristat Therapy
Introduction: Telotristat ethyl is a tryptophan hydroxylase inhibitor that has been shown to be effective against symptoms of carcinoid syndrome refractory to standard somatostatin analogue therapy by directly inhibiting serotonin production. While clinical trials have established short-term efficacy of the drug, we report an exploratory real-world study of 15 patients with metastatic neuroendocrine tumours on long-term Telotristat (median duration=8 months).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Doctor Shweta Hota
Authors: Hota S, Cananea E, Martin W, Clement D, ...
#3018 Real-Life Data for Telotristat Ethyl in Resistant-to-Treatment Carcinoid Syndrome: Is It Efficacious in Carcinoid Flushing as Well?
Introduction: Results from clinical trials with telotristat ethyl (TE) are really encouraging about its role in carcinoid syndrome-associated diarrhoea, however, its efficacy in flushing has been equivocal.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Dr Julian Gertner
Keywords: telotristat
#2750 Progression-Free Survival and Clinical Outcomes with Long-Term Use of Telotristat Ethyl in US Clinical Practice
Introduction: Treatment of advanced neuroendocrine tumors aims to relieve symptoms and suppress tumor growth. Primary findings from the TELEACE study suggested telotristat ethyl (TE) may reduce tumor size and impact tumor growth.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: David C. Metz
Authors: Metz D C, Liu E, Joish V N, Huynh L, ...
#3041 Resource Use in Patients with Carcinoid Syndrome: A Retrospective Analysis Using the French Health Insurance National (SNDS) Database
Introduction: About 20% of patients (pts) with neuroendocrine tumors (NET) suffer from carcinoid syndrome (CS), mainly from ileum and lung NET. Pts with CS experience symptoms such as diarrhea, flushes and cardiac complications. The diarrhea occurs in almost all pts with CS and can be truly debilitating. Therefore, on top of the tumor, the burden of the symptoms further impairs quality of life and is associated with additional costs related to symptom management and pts follow-up.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: PhD Delphine Gueguen
#2833 Surgical Correction of Carcinoid Heart Disease Improves Liver Function and 5-Hydroxyindoleacetic Acid Levels
Introduction: Neuroendocrine tumours of the gastrointestinal tract cause carcinoid syndrome and carcinoid heart disease. These tumours secrete serotonin, which can bind to heart valves and cause fibrosis and valve incompetence. Most cases involve the tricuspid valve +/- pulmonary valve. Medical management comprises diuretics for fluid overload and somatostatin analogues to reduce circulating serotonin. Definitive treatment is heart-valve replacement surgery which improves exercise tolerance but has high perioperative mortality. We have previously reported that valve-replacement surgery can reduce 5-hydroxyindoleacetic acid (5-HIAA) levels, reflecting a decline in hormone activity.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Dr Tahir Shah